ByzenCell Applies for Phase 1 IND of Recurrent Glioblastoma Treatment
[Asia Economy Reporter Junho Hwang] VigenCell announced on the 23rd that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of VT-Tri(2), a treatment for recurrent glioblastoma, to the Ministry of Food and Drug Safety.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Withdrew 1.2 Billion Won from Husband's Account Just Before Death"...Remarried Wife Receives Suspended Prison Sentence
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
